Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Clinical Trials

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Telisotuzumab Adizutecan
Drug: Fluorouracil
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Panitumumab
Drug: Bevacizumab

First Posted Date: 2025-02-11

Last Posted Date: 2025-04-27

Lead Sponsor: AbbVie

Target Recruit Count: 390

Registration Number: NCT06820463

Locations: 🇮🇱
Hadassah Medical Center-Hebrew University /ID# 268007, Jerusalem, Israel
🇮🇱
Rabin Medical Center /ID# 268008, Petah Tikva, Israel
🇺🇸
Yale New Haven Hospital /ID# 270565, New Haven, Connecticut, United States

and more 7 locations

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 3

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: Tislelizumab
Drug: Oxaliplatin injection
Drug: Levo-Leucovorin
Drug: 5-fluorouracil
Drug: Paclitaxel

First Posted Date: 2025-01-27

Last Posted Date: 2025-01-27

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 269

Registration Number: NCT06793917

Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV

Phase 1

Recruiting

Conditions: Advanced Pancreatic Cancer (Part 1)

Interventions: Drug: Irinotecan liposoma
Drug: 5-FU
Drug: Oxaliplatin
Drug: LV
Drug: bevacizumab
Drug: Irinotecan Liposomal

First Posted Date: 2025-01-20

Last Posted Date: 2025-01-20

Lead Sponsor: Dai, Guanghai

Target Recruit Count: 138

Registration Number: NCT06782685

Locations: 🇨🇳
Beijing, Beijing, China
🇨🇳
Chinese PLA General Hospital, Beijing, China

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Phase 2

Not yet recruiting

Conditions: Rectal Adenocarcinoma
Stage IIA Rectal Cancer AJCC v8
Stage III Rectal Cancer AJCC v8

Interventions: Biological: Balstilimab
Procedure: Biospecimen Collection
Biological: Botensilimab
Drug: Capecitabine
Procedure: Computed Tomography
Procedure: Digital Rectal Examination
Procedure: Endoscopic Biopsy
Drug: Fluorouracil
Drug: Leucovorin Calcium
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Radiation: Radiation Therapy
Procedure: Sigmoidoscopy

First Posted Date: 2025-01-17

Last Posted Date: 2025-01-17

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 26

Registration Number: NCT06780787

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

Phase 1

Not yet recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Biological: Pembrolizumab
Drug: Leucovorin
Biological: I-DXd
Drug: Levoleucovorin
Drug: 5-Fluorouracil (5-FU)
Drug: Oxaliplatin

First Posted Date: 2025-01-17

Last Posted Date: 2025-04-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 209

Registration Number: NCT06780111

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Cancer

Interventions: Drug: HCB101
Drug: Trastuzumab
Drug: Ramucirumab
Drug: Toripalimab
Drug: Pertuzumab
Drug: Paclitaxel
Drug: Albumin-bound paclitaxel
Drug: Oxaliplatin
Drug: Pembrolizumab
Drug: Bevacizumab
Drug: Capecitabine
Drug: Gemcitabine
Drug: Cetuximab
Drug: Irinotecan
Drug: Leucovorin
Drug: 5-FU

First Posted Date: 2025-01-13

Last Posted Date: 2025-04-04

Lead Sponsor: FBD Biologics Limited

Target Recruit Count: 150

Registration Number: NCT06771622

Locations: 🇨🇳
Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2

Recruiting

Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma
Stage I Bladder Cancer AJCC v8
Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

Interventions: Procedure: Biospecimen Collection
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Fluorouracil
Biological: Pembrolizumab
Drug: Gemcitabine
Procedure: Magnetic Resonance Imaging
Drug: Mitomycin
Other: Questionnaire Administration
Radiation: Radiation Therapy

First Posted Date: 2025-01-13

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 160

Registration Number: NCT06770582

Locations: 🇺🇸
Shaw Cancer Center, Edwards, Colorado, United States
🇺🇸
University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸
Louisiana Hematology Oncology Associates LLC, Baton Rouge, Louisiana, United States

and more 20 locations